HOME >> MEDICINE >> NEWS
Improvement seen in fetal survival following preeclampsia

Fetal survival following a preeclamptic pregnancy has improved substantially over the last 35 years in Norway, likely due to a reduction in stillbirths and improvements in clinical management, according to a study in the September 20 issue of JAMA.

Preeclampsia (a potentially dangerous condition that may develop in late pregnancy with symptoms that include high blood pressure, fluid retention, excessive weight gain, and the presence of protein in the urine) is a well-known cause of perinatal (occurring during the period around birth) death. Despite improvements in clinical management, preeclampsia often culminates in the delivery of a very preterm infant following medical intervention. Even mild preterm delivery substantially increases the risk of neonatal death. Preeclampsia can progress rapidly, putting both mother and child at severe risk if no action is taken. Medically indicated preterm delivery may help prevent stillbirth. This practice has increased in recent decades, but its net effect on fetal and infant survival has not been assessed.

Olga Basso, Ph.D., of the National Institute of Environmental Health Sciences, Research Triangle Park, N.C., and colleagues examined changes over time in perinatal and early childhood survival in relation to preeclampsia in Norway. The study included data from 804,448 first-born infants with Norwegian-born mothers and registered in the Medical Birth Registry of Norway between 1967 and 2003, including 770,613 pregnancies without preeclampsia and 33,835 pregnancies with preeclampsia.

The researchers found that among preeclamptic pregnancies, inductions before 37 weeks (of gestation) increased from 8 percent in 1967-1978 to nearly 20 percent in 1991-2003. In 1967-1978, more than 25 percent of all infants born before 34 completed weeks died in the neonatal period, as opposed to 5 percent in 1991-2003.

" preeclampsia was an important cause of fetal death in Norway during the late 1960
'"/>

Contact: Robin Mackar
919-541-0073
JAMA and Archives Journals
19-Sep-2006


Page: 1 2

Related medicine news :

1. Marked departure in Medicare practice of paying physicians in Geriatric Care Improvement Act
2. Improvements in critical care decrease risk of post-injury multiple organ failure
3. Benchmark fetal surgery study finds timeliness to be critical factor in success of treatment
4. First-degree fetal heart block may be reversible
5. Restricted fetal growth increases risk of irritable bowel syndrome
6. Methamphetamine use restricts fetal growth, study finds
7. Commonly used drug may prevent fetal alcohol syndrome
8. New eye movement test may help treat fetal alcohol syndrome
9. Lifestyle, rather than fetal or childhood factors, critical for adult bone health
10. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
11. Stem cell transplantation procedure results in long-term survival for amyloidosis patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Improvement seen fetal survival following preeclampsia

(Date:7/30/2014)... teaching hospital in Ireland has shown than many of them ... minimise the risk of entrapment. The report, published online in ... need for careful selection of patients for whom bedrails are ... and maintenance of hospital bed systems. , Bedrails are commonly ... However, although the risk for any individual is extremely low, ...
(Date:7/30/2014)... July 30, 2014 Victory Medical ... proud to announce the launch of a pediatric unit ... general surgery. The doctors working in the pediatrics departments ... infants, children, and adolescents. Dr. Timothy Cole, Dr. Dale ... McDuffie, Dr. Neelesh Mehendale, and Dr. Nicholas Peiffer lead ...
(Date:7/30/2014)... 30, 2014 Dialogic Inc. ... announced that DollarPhone, the largest privately owned calling ... Dialogic® ControlSwitchâ„¢ softswitch to offer enhanced ... portability (LNP) to both its wholesale and prepaid ... is able to power DollarPhone’s network infrastructure, allowing ...
(Date:7/30/2014)... 30, 2014 A formal complaint ... Office against the maker of the dialysis products ... Medical Care defrauded the state, its residents, physicians ... dialysates, before they were recalled in 2012. There ... these products pending in the U.S. District Court, ...
(Date:7/30/2014)... -- ,Middle-aged adults with a history of alcohol abuse ... develop severe memory problems later in life, according to ... findings could help doctors identify those at risk for ... drinking. "We already know there is an association ... -- that understanding is based on asking older people ...
Breaking Medicine News(10 mins):Health News:High frequency of potential entrapment gaps in hospital beds 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 3Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 2Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 3Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 2Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 3Health News:Adults Who've Abused Alcohol May Be at Risk for Memory Problems 2
(Date:7/29/2014)... 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... two healthcare conferences during the third quarter, the 2014 ... Global Healthcare 2014 Conference.  Alexza,s corporate presentation will be ... on each event are below: , 2014 ... in Boston , MA.  The format ...
(Date:7/29/2014)... Inc. (NYSE: CVD ) today reported results ... revenue was $639 million, representing 8.0% growth from the ... company reported earnings of $0.29 per diluted share in ... per diluted share of $0.95, up 21.5% over the ... impairment charges totaling $52.6 million, or $0.61 per share, ...
(Date:7/29/2014)... New technology in the form of a ... see and assess brain tissue more clearly while treating ... who released their findings today at the Society of ... Colorado Springs, CO. ... a specialty that facilitates stroke treatment by navigating a ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
Cached News: